Atreca (NASDAQ:BCEL) released its earnings results on Tuesday. The company reported ($0.57) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.66) by $0.09, Bloomberg Earnings reports.
Shares of BCEL traded down $0.47 on Wednesday, reaching $11.05. The stock had a trading volume of 10,139 shares, compared to its average volume of 100,485. The company’s 50-day moving average price is $11.26. Atreca has a 12-month low of $9.59 and a 12-month high of $23.65.
BCEL has been the subject of a number of research analyst reports. Roth Capital initiated coverage on Atreca in a research note on Wednesday, September 4th. They issued a “buy” rating and a $30.00 target price for the company. Cowen restated a “buy” rating on shares of Atreca in a research note on Wednesday, August 14th. Finally, Brookline Capital Management restated a “buy” rating on shares of Atreca in a research note on Tuesday, August 20th. Six research analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and a consensus price target of $24.41.
Atreca, Inc, a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform.
Read More: Day Trading – Risk Worth the Reward?
Receive News & Ratings for Atreca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atreca and related companies with MarketBeat.com's FREE daily email newsletter.